The history of primary myelofibrosis dates back to 1951 and the description of four distinct clinicopathologic entities that came to be known as myeloproliferative neoplasms (MPNs): chronic myeloid ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Up until fairly ...
John Mascarenhas, MD, describes how the SOHO 2025 MPN session highlighted the four approved JAK inhibitors — ruxolitinib, momelotinib, pacritinib, and fedratinib — allowing for personalized treatment ...
Ajax Therapeutics Inc. has received clearance for its IND application from the FDA to initiate a phase I study of AJ1‑11095, a first-in-class type II JAK2 inhibitor, for the treatment of patients with ...
NEW YORK & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ajax Therapeutics, Inc., a biopharmaceutical company developing next generation JAK inhibitors for patients with myeloproliferative neoplasms (MPNs), ...
Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics, today announced that OPN-2853, a ...
The development of new or worsening anemia did not decrease Jakafi’s efficacy in treating primary or secondary myelofibrosis. Patients with primary or secondary myelofibrosis who developed new or ...
– Nuvisertib (TP-3654), an investigational highly selective oral PIM1 kinase inhibitor, is being evaluated in patients with relapsed or refractory myelofibrosis (MF) – – Nuvisertib demonstrated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results